ERBB2 and breast carcinoma: In treatment-naïve patients with HR+, HER2– advanced breast cancer, gedatolisib in combination with palbociclib and letrozole induced an ORR of 79% among evaluable patients, a median PFS of 48.4 months, and a median OS of 77.3 months.